Health Bulletin 18/February/2022

Published On 2022-02-18 11:51 GMT   |   Update On 2022-02-18 11:51 GMT
Advertisement

Here are Top Health stories of the day

Hacking: Anti-hijab tweet on doc's account  

Dr Shantanu R Prabhu, a pediatrician in Ujire, said in a complaint that the anti-hijab tweet appeared on his account aimed at tarnishing his image, police sources said.

A Ujire doctor in Dakshina Kannada region has complained to police that his  twitter account has been hijacked by unscrupulous people who have posted anti-hijab inscriptions on it.

Advertisement


National Action Plan On Antimicrobial Resistance: NMC Directs Medical Colleges To Nominate Nodal Officers

Reminding the medical colleges about the growing threat of Antimicrobial Resistance (AMR), the NMC has recently written to the heads of the medical institutes to inform them about the National Action Plan (NAP), developed by the Union Ministry of Health and Family Welfare.

In the letter, the Officer Incharge of NAP-AMR of NMC, Dr. Vijaya Lakshmi Nag has directed the medical colleges to nominate One Nodal Officer, preferably at the level of Professor/ Addl. Professor from any of the Department of Microbiology, Pharmacology, Medicine or Community Medicine for future interaction/ discussions on the subject.

For more details, check out the full story on the link below:

National Action Plan On Antimicrobial Resistance: NMC Directs Medical Colleges To Nominate Nodal Officers


India reports outbreak of H5N1 bird flu - OIE

India 3 reported an outbreak of the highly contagious bird H5N1 virus on a poultry farm in the northeastern Bihar region, 3.1 The World Organization for Animal Health (OIE) said on Wednesday.

The virus has killed 787 of the 3,859 birds on a farm in Patna and killed the remaining 3.2 birds, the Paris-based OIE said, citing a report by Indian authorities.


Study: Breast cancer cases rise, cervical cancer dips


Sun Pharma gets CDSCO nod to market Tofacitinib to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis

In a significant development, the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) has granted approval to pharma major Sun Pharmaceuticals to manufacture and market Tofacitinib ER Tablets 11mg for the treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis.

This came after the drug maker Sun Pharma presented the proposal for manufacturing and marketing of Tofacitinib ER Tablets 11mg along with bioavailability (BE) Study report before the committee.

For more details, check out the full story on the link below:

 Sun Pharma Gets CDSCO Nod To Market Tofacitinib To Treat Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis  

Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News